A Pilot Randomized Trial of Oral Magnesium Supplementation on Supraventricular Arrhythmias
Lutsey PL, Chen LY, Eaton A, Jaeb M, Rudser KD, Neaton JD, Alonso A
Nutrients · 22 citations
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- Nonprofit
- American Heart Association
- Nonprofit
- American Heart Association-American Stroke Association
- Grants
- American Heart Association (16EIA26410001)
Based on 2 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2018-07-10 · Nutrients · vol. 10 · issue 7 · p. 884
- Publisher
- Multidisciplinary Digital Publishing Institute
- Cited
- 26 citations · more than 84% of similar papers · 1.6× the field average
- References
- 32 works
- Access
- Open access (journal) · CC-BY
- Research areas
- Atrial Fibrillation Management and Outcomes · Cardiac Arrhythmias and Treatments · Magnesium in Health and Disease
- Keywords
- Medicine, Placebo, Magnesium, Randomized controlled trial, Atrial fibrillation, Ambulatory, Pill, Confidence interval, Internal medicine, Anesthesia, Pharmacology
- MeSH
- humans, atrial fibrillation, atrial premature complexes, magnesium oxide, anti-arrhythmia agents, electrocardiography, ambulatory, treatment outcome, administration, oral, feasibility studies, pilot projects, double-blind method, predictive value of tests, transducers, heart rate, time factors, dietary supplements, signal processing, computer-assisted, aged, middle aged, minnesota, female, male, medication adherence
7 authors
From US
- Pamela L. Lutsey · correspondingUniversity of Minnesota
- Lin Y. ChenUniversity of Minnesota
- Anne A. EatonUniversity of Minnesota
- Melanie A. JaebUniversity of Minnesota
- Kyle D. RudserUniversity of Minnesota
- James D. NeatonUniversity of Minnesota
Abstract
Low magnesium may increase the risk of atrial fibrillation. We conducted a double-blind pilot randomized trial to assess adherence to oral magnesium supplementation (400 mg of magnesium oxide daily) and a matching placebo, estimate the effect on circulating magnesium concentrations, and evaluate the feasibility of using an ambulatory heart rhythm monitoring device (ZioPatch) for assessing premature atrial contractions. A total of 59 participants were randomized; 73% were women, and the mean age was 62 years. A total of 98% of the participants completed the follow-up. In the magnesium supplement group, 75% of pills were taken, and in the placebo group, 83% were taken. The change in magnesium concentrations was significantly greater for those given the magnesium supplements than for those given the placebo (0.07; 95% confidence interval: 0.03, 0.12 mEq/L; p = 0.002). The ZioPatch wear time was approximately 13 of the requested 14 days at baseline and follow-up. There was no difference by intervention assignment in the change in log premature atrial contractions burden, glucose, or blood pressure. Gastrointestinal changes were more common among the participants assigned magnesium (50%) than among those assigned the placebo (7%), but only one person discontinued participation. In sum, compliance with the oral magnesium supplementation was very good, and acceptance of the ZioPatch monitoring was excellent. These findings support the feasibility of a larger trial for atrial fibrillation (AF) prevention with oral magnesium supplementation.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.